Diaceutics PLC New contract win for DXRX platform (6787T)
22 July 2020 - 4:00PM
UK Regulatory
TIDMDXRX
RNS Number : 6787T
Diaceutics PLC
22 July 2020
Diaceutics PLC
("Diaceutics" or the "Group" or the "Company")
New contract win for DXRX platform
Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation
company, announces a significant new client contract win with a
leading pharmaceutical company.
Diaceutics' will collaborate with this new client to produce an
outsourced commercial solution for its US market, using the
Company's new DXRX platform to improve patient testing and support
the client's pioneering activities in the field of immunotherapy.
This initial contract is worth $1.27 million.
The end-to-end diagnostic development and commercialisation
service to be provided to this client evidences the evolution of
Diaceutics' business model. The introduction of DXRX marks the
shift from historical consulting and planned platform services to a
broader client offering which brings together Diaceutics' propriety
intellectual property, global laboratory network and repository of
testing data on one proprietary platform, on a longer term basis.
DXRX will enable the client to deliver seamless diagnostic testing
for their precision medicine therapies which will result in greater
efficiencies and drive increased testing rates and adoption.
Commenting on today's news, Peter Keeling, Diaceutics' Chief
Executive said:
"This client win marks another milestone in the commercial
success of Diaceutics. Our data and new commercialisation platform
DXRX are designed to provide a full end-to-end service, and via
these we believe we are well placed to significantly improve
patient testing for our clients' therapy in this challenging cancer
setting."
Enquiries:
Diaceutics PLC
Stuart Hunt, Head of Investor Relations Tel: +44 (0)7815 778
536
Cenkos Securities PLC (Nomad & Broker) Tel: +44(0)20 7397
8900
Callum Davidson / Giles Balleny
Michael Johnson (Sales)
Walbrook PR Tel: +44 (0)20 7933 8780 or diaceutics@walbrookpr.com
Anna Dunphy Tel: +44 (0)7876 741
001
Paul McManus Tel: +44 (0)7980 541
893
About Diaceutics
At Diaceutics we believe that every patient should get the
precision medicine they deserve. We are a data analytics and
end-to-end services provider enabled by DXRX - the world's first
Diagnostic Network solution for the development and
commercialisation of precision medicine diagnostics. The Group,
listed on the AIM Market of the London Stock Exchange, has created
commercially useful data sets for every precision medicine that has
come to market. We have built the world's largest repository of
diagnostic testing data with a growing network of 2500 labs in 51
countries. www.diaceutics.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
CNTEAKXFAALEEFA
(END) Dow Jones Newswires
July 22, 2020 02:00 ET (06:00 GMT)
Diaceutics (LSE:DXRX)
Historical Stock Chart
From Apr 2024 to May 2024
Diaceutics (LSE:DXRX)
Historical Stock Chart
From May 2023 to May 2024